• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

    11/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    Highlights

    • Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency
    • Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidance
    • Instruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growth
    • Recurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations products
    • In constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the Americas
    • Raising full-year 2025 constant currency sales growth guidance and raising full-year 2025 non-GAAP EPS guidance

    Third Quarter 2025

    MILFORD, Mass., Nov. 4, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the third quarter of 2025.

    Sales for the third quarter of 2025 were $800 million, an increase of 8% as reported and 8% in constant currency, compared to sales of $740 million for the third quarter of 2024.

    On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2025 were $2.50, compared to $2.71 for the third quarter of 2024. Non-GAAP EPS for the third quarter of 2025 grew 16% to $3.40, compared to $2.93 for the third quarter of 2024.

    "Our team yet again delivered outstanding results, driven by strong execution and our differentiated product portfolio. Pharma grew double digits as the instrument replacement cycle entered its second year, and new LC-MS and chemistry products captured opportunities from the growing share of biologics and novel modalities in the pharma pipeline," said Dr. Udit Batra, President & CEO of Waters Corporation.

    Dr. Batra continued, "Our chemistry portfolio continues to set the standard in the industry, with excellent customer reception of our new Affinity bioseparation columns. In bioanalytical characterization, we have worked closely with customers to develop the Xevo™ Charge Detection Mass Spectrometer, which uses up to 100-fold less sample volume than current techniques and delivers results in under 10 minutes."

    "We will uphold the same high standards of innovation, operational excellence, and execution in BD's Biosciences & Diagnostic Solutions business as we accelerate our long-term growth strategy. Integration planning is progressing as expected, and we remain highly confident in the achievability of the significant cost and revenue synergies we have identified."

    A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section.

    Full-Year and Fourth Quarter 2025 Financial Guidance

    Full-Year 2025 Financial Guidance

    The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +6.7% to +7.3%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%.

    The Company is raising its full-year 2025 non-GAAP EPS guidance to the range of $13.05 to $13.15. This reflects year-over-year growth of approximately +10% to +11% and +11% to +12% on a constant currency basis.

    Fourth Quarter 2025 Financial Guidance

    The Company expects fourth quarter 2025 constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, fourth quarter 2025 reported sales growth is expected in the range of +5.2% to +7.2%.

    The Company expects fourth quarter 2025 non-GAAP EPS to be in the range of $4.45 to $4.55, which reflects year-over-year growth of approximately +9% to +11%.

    Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year and fourth quarter.

    Conference Call Details

    Waters Corporation will webcast its third quarter 2025 financial results conference call today, November 4, 2025, at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select "Investor Relations" under the "About Waters" section, navigate to "Events & Presentations," and click on the "Webcast." A replay will be available through at least December 2, 2025.

    About Waters Corporation

    Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

    Additional Information and Where to Find It

    This release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"), and otherwise in accordance with applicable law.

    In connection with the proposed transaction between Waters, Augusta SpinCo Corporation ("SpinCo") and Becton, Dickinson and Company ("BD"), the parties intend to file relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including, among other filings, a registration statement on Form S-4 to be filed by Waters (the "Form S-4") that will include a preliminary proxy statement/prospectus of Waters and a definitive proxy statement/prospectus of Waters, the latter of which will be mailed to stockholders of Waters, and a registration statement on Form 10 to be filed by SpinCo that will incorporate by reference certain portions of the Form S-4 and will serve as an information statement/prospectus in connection with the spin-off of SpinCo from BD. INVESTORS AND SECURITY HOLDERS OF WATERS AND BD ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, THE INFORMATION STATEMENT/PROSPECTUS AND ANY OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders will be able to obtain free copies of the Form S-4 and the proxy statement/prospectus (when available) and other documents filed with the SEC by Waters, SpinCo or BD through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Waters will be available free of charge on Waters' website at waters.com under the tab "About Waters" and under the heading "Investor Relations" and subheading "Financials—SEC Filings." Copies of the documents filed with the SEC by BD and SpinCo will be available free of charge on BD's website at bd.com under the tab "About BD" and under the heading "Investors" and subheading "SEC Filings."

    Participants in the Solicitation

    Waters and BD and their respective directors and executive officers may be considered participants in the solicitation of proxies from Waters' stockholders in connection with the proposed transaction. Information about the directors and executive officers of Waters is set forth in its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 25, 2025, and its proxy statement for its 2025 annual meeting, which was filed with the SEC on April 9, 2025. To the extent holdings of Waters' securities by its directors or executive officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Information about the directors and executive officers of Waters and other information regarding the potential participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction. Information about the directors and executive officers of BD is set forth in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed with the SEC on November 27, 2024, and its proxy statement for its 2025 annual meeting, which was filed with the SEC on December 19, 2024. To the extent holdings of BD's securities by its directors or executive officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at www.sec.gov and from Waters' website and BD's website as described above.

    Non-GAAP Financial Measures

    This release contains financial measures, such as constant currency growth rates, adjusted earnings per diluted share and free cash flow, among others, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Definitions of the non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

    Cautionary Statement

    This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Our actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks or uncertainties related to expectations regarding our strategy, our future financial and operational performance, future economic and market conditions, including our expectations about the growth rates of certain markets, our strategic initiatives, including  our instrument replacement initiatives, respond and adapt to changing global dynamics, including the potential impacts of tariffs and supply chain challenges, the potential impacts of the U.S. government shutdown that began in October 2025, our ability to retain and attract customers in various geographies and market segments, our market size and growth opportunities, our competitive positioning, projected costs, technological capabilities and plans, and objectives of management. Furthermore, important factors related to the proposed transaction between Waters, BD and SpinCo could cause actual results to differ materially from those currently anticipated, including that one or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived, on a timely basis or otherwise, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction, may require conditions, limitations or restrictions in connection with such approvals or that the required approval by the stockholders of Waters may not be obtained, the risk that the proposed transaction may not be completed on the terms or in the time frame expected by Waters, or at all, unexpected costs, charges or expenses resulting from the proposed transaction,  uncertainty of the expected financial performance of the combined company following completion of the proposed transaction, failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all, the ability of the combined company to implement its business strategy, difficulties and delays in the combined company achieving revenue and cost synergies, inability of the combined company to retain and hire key personnel, the occurrence of any event that could give rise to termination of the proposed transaction, the risk that stockholder litigation in connection with the proposed transaction or other litigation, settlements or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability, evolving legal, regulatory and tax regimes, changes in general economic and/or industry specific conditions or any volatility resulting from the imposition of and changing policies around tariffs, actions by third parties, including government agencies, the risk that the anticipated tax treatment of the proposed transaction is not obtained, the risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD, risks related to the disruption of management time from ongoing business operations due to the pendency of the proposed transaction, or other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties; and other risk factors detailed from time to time in Waters' reports filed with the SEC. Such factors and others are discussed more fully in the sections entitled "Forward-Looking Statements" and "Risk Factors" of the Company's annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission ("SEC"), which discussions are incorporated by reference in this release, as updated by the Company's future filings with the SEC. The forward-looking statements included in this release represent the Company's estimates or views as of the date of this release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

     

    Waters Corporation and Subsidiaries

    Consolidated Statements of Operations

    (In thousands, except per share data)

    (Unaudited)































    Three Months Ended



    Nine Months Ended



    September 27,

    2025



    September 28,

    2024



    September 27,

    2025



    September 28,

    2024

















    Net sales

    $              799,887



    $              740,305



    $           2,232,924



    $           2,085,673

















    Costs and operating expenses:















    Cost of sales

    327,806



    301,655



    925,958



    851,685

    Selling and administrative expenses 

    214,229



    169,097



    590,367



    516,880

    Research and development expenses 

    53,643



    45,336



    148,813



    136,113

    Purchased intangibles amortization 

    12,095



    11,759



    35,714



    35,337

    Litigation provision

    -



    1,326



    -



    11,568

















    Operating income 

    192,114



    211,132



    532,072



    534,090

















    Other (expense) income, net

    (70)



    (338)



    778



    1,619

    Interest expense, net

    (21,925)



    (17,177)



    (42,153)



    (57,824)

















    Income from operations before income taxes

    170,119



    193,617



    490,697



    477,885

















    Provision for income taxes

    21,196



    32,114



    73,282



    71,449

















    Net income

    $              148,923



    $              161,503



    $              417,415



    $              406,436

































    Net income per basic common share

    $                    2.50



    $                    2.72



    $                    7.02



    $                    6.85

















    Weighted-average number of basic common shares

    59,528



    59,367



    59,496



    59,314

































    Net income per diluted common share

    $                    2.50



    $                    2.71



    $                    7.00



    $                    6.83

















    Weighted-average number of diluted common shares and equivalents

    59,622



    59,504



    59,656



    59,471

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP

    Net Sales by Operating Segments, Products & Services, Geography and Markets

    Three Months Ended September 27, 2025 and September 28, 2024

    (In thousands)

































































    Constant











    Three Months Ended



    Percent



    Impact of



    Currency











    September 27, 2025



    September 28, 2024



    Change



    Currency



    Growth Rate (a)

































    NET SALES - OPERATING SEGMENTS

























































    Waters





    $

    713,375



    $

    655,652



    9 %



    0 %



    9 %

    TA









    86,512





    84,653



    2 %



    1 %



    2 %

































    Total







    $

    799,887



    $

    740,305



    8 %



    0 %



    8 %

































































    NET SALES - PRODUCTS & SERVICES

























































    Instruments





    $

    341,484



    $

    323,076



    6 %



    0 %



    6 %

































    Service







    299,923





    278,294



    8 %



    1 %



    7 %

    Chemistry







    158,480





    138,935



    14 %



    1 %



    13 %

    Total Recurring







    458,403





    417,229



    10 %



    1 %



    9 %

































    Total







    $

    799,887



    $

    740,305



    8 %



    0 %



    8 %

































































    NET SALES - GEOGRAPHY

























































    Asia







    $

    269,714



    $

    251,329



    7 %



    (5 %)



    13 %

    Americas







    292,812





    279,136



    5 %



    0 %



    5 %

    Europe







    237,361





    209,840



    13 %



    8 %



    5 %

































    Total







    $

    799,887



    $

    740,305



    8 %



    0 %



    8 %

































































    NET SALES - MARKETS

























































    Pharmaceutical





    $

    479,776



    $

    430,138



    12 %



    1 %



    11 %

    Industrial







    235,669





    227,740



    3 %



    (1 %)



    4 %

    Academic & Government





    84,442





    82,427



    2 %



    1 %



    1 %

































    Total







    $

    799,887



    $

    740,305



    8 %



    0 %



    8 %

    ________________________________________





    (a)

    The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP

    Net Sales by Operating Segments, Products & Services, Geography and Markets

    Nine Months Ended September 27, 2025 and September 28, 2024

    (In thousands)

































































    Constant











    Nine Months Ended



    Percent



    Impact of



    Currency











    September 27, 2025



    September 28, 2024



    Change



    Currency



    Growth Rate (a)

































    NET SALES - OPERATING SEGMENTS

























































    Waters





    $

    1,989,509



    $

    1,840,112



    8 %



    0 %



    9 %

    TA









    243,415





    245,561



    (1 %)



    1 %



    (1 %)

































    Total







    $

    2,232,924



    $

    2,085,673



    7 %



    0 %



    7 %

































































    NET SALES - PRODUCTS & SERVICES

























































    Instruments





    $

    912,792



    $

    859,079



    6 %



    0 %



    7 %

































    Service







    859,030





    812,367



    6 %



    (1 %)



    6 %

    Chemistry







    461,102





    414,227



    11 %



    0 %



    11 %

    Total Recurring







    1,320,132





    1,226,594



    8 %



    0 %



    8 %

































    Total







    $

    2,232,924



    $

    2,085,673



    7 %



    0 %



    7 %

































































    NET SALES - GEOGRAPHY

























































    Asia







    $

    756,430



    $

    696,319



    9 %



    (5 %)



    13 %

    Americas







    829,089





    794,775



    4 %



    0 %



    5 %

    Europe







    647,405





    594,579



    9 %



    4 %



    5 %

































    Total







    $

    2,232,924



    $

    2,085,673



    7 %



    0 %



    7 %

































































    NET SALES - MARKETS

























































    Pharmaceutical





    $

    1,332,795



    $

    1,220,092



    9 %



    (1 %)



    10 %

    Industrial







    676,689





    644,459



    5 %



    0 %



    5 %

    Academic & Government





    223,440





    221,122



    1 %



    1 %



    0 %

































    Total







    $

    2,232,924



    $

    2,085,673



    7 %



    0 %



    7 %

    ________________________________________





    (a)

    The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP Financials

    Three and Nine Months Ended September 27, 2025 and September 28, 2024

    (In thousands, except per share data)

































































































































































    Income from



























































    Operations





























    Selling &





    Research &











    Operating





    Interest





    before





    Provision for











    Diluted











    Administrative





    Development





    Operating





    Income





    Expense,





    Income





    Income





    Net





    Earnings











    Expenses(a)





    Expenses





    Income





    Percentage





    Net





    Taxes





    Taxes





    Income





    per Share

    Three Months Ended September 27, 2025























































    GAAP





    $

    226,324



    $

    53,643



    $

    192,114





    24.0 %



    $

    (21,925)



    $

    170,119



    $

    21,196



    $

    148,923



    $

    2.50

    Adjustments:



























































    Purchased intangibles amortization (b)





    (12,095)





    -





    12,095





    1.5 %





    -





    12,095





    2,894





    9,201





    0.15



    Restructuring costs and certain other items (c)





    (1,279)





    -





    1,279





    0.2 %





    -





    1,279





    288





    991





    0.02



    ERP implementation and transformation costs (d)





    (6,434)





    -





    6,434





    0.8 %





    -





    6,434





    1,544





    4,890





    0.08



    Acquisition related costs (e)





    (26,809)





    (3,735)





    30,544





    3.8 %





    -





    30,544





    2,338





    28,206





    0.47



    Financing Costs (h)





    -





    -





    -





    -





    14,060





    14,060





    3,374





    10,686





    0.18

    Adjusted Non-GAAP



    $

    179,707



    $

    49,908



    $

    242,466





    30.3 %



    $

    (7,865)



    $

    234,531



    $

    31,634



    $

    202,897



    $

    3.40





























































    Three Months Ended September 28, 2024























































    GAAP





    $

    182,182



    $

    45,336



    $

    211,132





    28.5 %



    $

    (17,177)



    $

    193,617



    $

    32,114



    $

    161,503



    $

    2.71

    Adjustments:



























































    Purchased intangibles amortization (b)





    (11,759)





    -





    11,759





    1.6 %





    -





    11,759





    2,814





    8,945





    0.15



    Restructuring costs and certain other items (c)





    (1,194)





    -





    1,194





    0.2 %





    -





    1,194





    282





    912





    0.02



    Litigation provision (f)





    (1,326)





    -





    1,326





    0.2 %





    -





    1,326





    318





    1,008





    0.02



    Retention bonus obligation (g)





    (1,909)





    (636)





    2,545





    0.3 %





    -





    2,545





    611





    1,934





    0.03

    Adjusted Non-GAAP



    $

    165,994



    $

    44,700



    $

    227,956





    30.8 %



    $

    (17,177)



    $

    210,441



    $

    36,139



    $

    174,302



    $

    2.93





























































    Nine Months Ended September 27, 2025























































    GAAP





    $

    626,081



    $

    148,813



    $

    532,072





    23.8 %



    $

    (42,153)



    $

    490,697



    $

    73,282



    $

    417,415



    $

    7.00

    Adjustments:



























































    Purchased intangibles amortization (b)





    (35,714)





    -





    35,714





    1.6 %





    -





    35,714





    8,546





    27,168





    0.46



    Restructuring costs and certain other items (c)





    (5,746)





    -





    5,746





    0.3 %





    -





    5,746





    1,344





    4,402





    0.07



    ERP implementation and transformation costs (d)





    (13,811)





    -





    13,811





    0.6 %





    -





    13,811





    3,315





    10,496





    0.18



    Acquisition related costs (e)





    (41,093)





    (3,735)





    44,828





    2.0 %





    -





    44,828





    4,729





    40,099





    0.67



    Retention bonus obligation (g)





    (2,864)





    (954)





    3,818





    0.2 %





    -





    3,818





    916





    2,902





    0.05



    Financing Costs (h)





    -





    -





    -





    -





    14,060





    14,060





    3,374





    10,686





    0.18

    Adjusted Non-GAAP



    $

    526,853



    $

    144,124



    $

    635,989





    28.5 %



    $

    (28,093)



    $

    608,674



    $

    95,506



    $

    513,168



    $

    8.60





























































    Nine Months Ended September 28, 2024























































    GAAP





    $

    563,785



    $

    136,113



    $

    534,090





    25.6 %



    $

    (57,824)



    $

    477,885



    $

    71,449



    $

    406,436



    $

    6.83

    Adjustments:



























































    Purchased intangibles amortization (b)





    (35,337)





    -





    35,337





    1.7 %





    -





    35,337





    8,456





    26,881





    0.45



    Restructuring costs and certain other items (c)





    (10,680)





    -





    10,680





    0.5 %





    -





    10,680





    2,617





    8,063





    0.14



    Litigation provision and settlement (f)





    (11,568)





    -





    11,568





    0.6 %





    -





    11,568





    2,776





    8,792





    0.15



    Retention bonus obligation (g)





    (11,451)





    (3,817)





    15,268





    0.7 %





    -





    15,268





    3,664





    11,604





    0.20

    Adjusted Non-GAAP



    $

    494,749



    $

    132,296



    $

    606,943





    29.1 %



    $

    (57,824)



    $

    550,738



    $

    88,962



    $

    461,776



    $

    7.76

    ________________________________________





    (a)

    Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements.

    (b)

    The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

    (c)

    Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

    (d)

    ERP implementation and transformation costs represent costs related to the Company's initiative to transition from its legacy enterprise resource planning (ERP) system to a new global ERP solution with a cloud-based infrastructure. These costs, which do not represent normal or future ongoing business expenses, are one-time, non-recurring costs related to the establishment of our new global ERP solution that were determined to be non-capitalizable in accordance with accounting standards.

    (e)

    Acquisition related costs include all incremental costs incurred to effect the business combination, such as advisory, legal, accounting, tax, valuation, other professional fees, and integration costs. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

    (f)

    Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly.

    (g)

    In connection with the Wyatt acquisition, the Company recognized a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

    (h)

    Financing costs relate to certain financing fees incurred by the Company to secure access to certain debt facilities in connection with the agreement Waters entered into to acquire the Biosciences and Diagnostics Solutions business of Becton, Dickinson & Company. The Company believes that these costs are not normal and do not represent future ongoing business expenses. 

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Unclassified Consolidated Balance Sheets

    (In thousands and unaudited)











































    September 27, 2025



    December 31, 2024

















    Cash and cash equivalents





    $              459,118



    $              325,355

    Accounts receivable







    748,519



    733,365

    Inventories







    572,941



    477,261

    Property, plant and equipment, net



    636,964



    651,200

    Intangible assets, net







    570,773



    567,906

    Goodwill









    1,338,358



    1,295,720

    Other assets







    535,891



    502,988

       Total assets







    $           4,862,564



    $           4,553,795

































    Notes payable and debt





    $           1,407,206



    $           1,626,488

    Other liabilities







    1,124,665



    1,098,800

       Total liabilities







    2,531,871



    2,725,288

















    Total stockholders' equity





    2,330,693



    1,828,507

       Total liabilities and stockholders' equity



    $           4,862,564



    $           4,553,795

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Consolidated Statements of Cash Flows

    Three and Nine Months Ended September 27, 2025 and September 28, 2024

    (In thousands and unaudited)



































    Three Months Ended





    Nine Months Ended









    September 27, 2025



    September 28, 2024





    September 27, 2025



    September 28, 2024

















    Cash flows from operating activities:



















    Net income

    $                    148,923



    $                    161,503





    $                    417,415



    $                     406,436



    Adjustments to reconcile net income to net























    cash provided by operating activities:





















    Stock-based compensation

    13,650



    10,647





    39,625



    32,993





    Depreciation and amortization

    52,678



    47,507





    153,696



    143,250





    Change in operating assets and liabilities and other, net

    (27,943)



    (15,077)





    (122,734)



    (60,695)







    Net cash provided by operating activities

    187,308



    204,580





    488,002



    521,984

























    Cash flows from investing activities:



















    Additions to property, plant, equipment























    and software capitalization

    (25,436)



    (25,618)





    (73,772)



    (90,377)



    Business acquisitions, net of cash acquired

    (84)



    -





    (35,053)



    -



    Investments in unaffiliated companies

    -



    (425)





    (1,295)



    (1,489)



    Net change in investments

    -



    (8)





    -



    (44)







    Net cash used in investing activities

    (25,520)



    (26,051)





    (110,120)



    (91,910)

























    Cash flows from financing activities:



















    Net change in debt

    (68,480)



    (180,000)





    (242,986)



    (530,000)



    Proceeds from stock plans

    2,883



    3,237





    15,621



    25,073



    Purchases of treasury shares

    (214)



    (141)





    (14,523)



    (13,475)



    Other cash flow from financing activities, net

    (455)



    20





    1,347



    15,305







    Net cash used in financing activities

    (66,266)



    (176,884)





    (240,541)



    (503,097)

























    Effect of exchange rate changes on cash and cash equivalents

    (3,619)



    2,442





    (3,578)



    8,461







    Increase (decrease) in cash and cash equivalents

    91,903



    4,087





    133,763



    (64,562)

























    Cash and cash equivalents at beginning of period

    367,215



    326,427





    325,355



    395,076







    Cash and cash equivalents at end of period

    $                    459,118



    $                    330,514





    $                    459,118



    $                     330,514

































































































    Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)









































































    Net cash provided by operating activities - GAAP

    $                    187,308



    $                    204,580





    $                    488,002



    $                     521,984



























    Adjustments:





















    Additions to property, plant, equipment























    and software capitalization

    (25,436)



    (25,618)





    (73,772)



    (90,377)





    Tax reform payments

    -



    -





    120,006



    95,645





    Litigation settlements (received) paid, net

    (2,250)



    -





    (2,250)



    9,250





    Payment of Wyatt retention bonus obligation (b)

    -



    -





    20,127



    19,770

    Free Cash Flow - Adjusted Non-GAAP

    $                    159,622



    $                    178,962





    $                    552,113



    $                     556,272





    (a)

    The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.





    (b)

    During the nine months ended September 27, 2025 and September 28, 2024, the Company made retention payments under the Wyatt retention bonus program. The Company believes that these payments are not normal and do not represent future ongoing business expenses.

     

    Waters Corporation and Subsidiaries

    Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook



















































    Twelve Months Ended



    Three Months Ended









    December 31, 2025



    December 31, 2025











    Range







    Range





    Projected Sales







































    Constant currency sales growth rate (a)

    6.7 %

    -

    7.3 %



    5.0 %

    -

    7.0 %



    Currency translation impact

    (0.2 %)

    -

    (0.2 %)



    0.2 %

    -

    0.2 %



    Sales growth rate as reported

    6.5 %

    -

    7.1 %



    5.2 %

    -

    7.2 %























































    Range







    Range





    Projected Earnings Per Diluted Share







































    GAAP earnings per diluted share

    $   11.10

    -

    $   11.20



    $     4.10

    -

    $     4.20



    Adjustments:





















    Purchased intangibles amortization 

    $     0.60

    -

    $     0.60



    $     0.15

    -

    $     0.15





    Restructuring costs and certain other items 

    $     0.08

    -

    $     0.08



    $     0.01

    -

    $     0.01





    ERP implementation and transformation costs 

    $     0.25

    -

    $     0.25



    $     0.07

    -

    $     0.07





    Acquisition related costs

    $     0.78

    -

    $     0.78



    $     0.11

    -

    $     0.11





    Retention bonus obligation

    $     0.05

    -

    $     0.05



    $        -

    -

    $        -





    Financing Costs

    $     0.19

    -

    $     0.19



    $     0.01

    -

    $     0.01



    Adjusted non-GAAP earnings per diluted share

    $   13.05

    -

    $   13.15



    $     4.45

    -

    $     4.55







    (a)

    Constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results.





    These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.

     

    Contact:    Caspar Tudor, Head of Investor Relations – (508) 482-3448

    Cision View original content:https://www.prnewswire.com/news-releases/waters-corporation-nyse-wat-reports-third-quarter-2025-financial-results-302603102.html

    SOURCE Waters Corporation

    Get the next $WAT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    10/8/2025$390.00Buy
    Rothschild & Co Redburn
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    More analyst ratings

    $WAT
    SEC Filings

    View All

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    11/4/25 5:01:03 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Waters Corporation

    10-Q - WATERS CORP /DE/ (0001000697) (Filer)

    11/4/25 7:05:56 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    11/4/25 7:00:06 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on Waters with a new price target

    Rothschild & Co Redburn initiated coverage of Waters with a rating of Buy and set a new price target of $390.00

    10/8/25 8:37:34 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

    3/31/25 7:57:55 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

    3/26/25 7:47:54 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Richard Fearon to Board of Directors

    Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

    3/28/23 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

    Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currencyDelivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidanceInstruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growthRecurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations productsIn constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the AmericasRaising full-year 2025 constant currency sales growth guidance and raisi

    11/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

    Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3MILFORD, Mass., Oct. 13, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterization for the broadest range of mega-mass biomolecules central to next-ge

    10/13/25 8:05:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 2nd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety

    10/1/25 12:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Knight Heather was granted 78 shares, increasing direct ownership by 11% to 759 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:16:38 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Jiang Wei was granted 73 shares, increasing direct ownership by 3% to 2,551 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:15:15 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Knight Heather was granted 68 shares, increasing direct ownership by 11% to 681 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    7/1/25 7:20:58 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

    Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currencyDelivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidanceInstruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growthRecurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations productsIn constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the AmericasRaising full-year 2025 constant currency sales growth guidance and raisi

    11/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 2nd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety

    10/1/25 12:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results

    Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currencyGAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customersRecurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growthIn constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expectedRaising full-year 2025 constant currency sales growth guidance to +5.5% to

    8/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials